News

CL-H1T, which contains fast-dissolving promethazine and sumatriptan, is being developed to treat migraine headache pain and migraine-induced nausea and vomiting (MINV). Charleston Laboratories chief scientific officer Bernard Schachtel

In November 2011, Synthon filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a once daily 20mg/ml formulation of glatiramer acetate,

The acquisition will give Shire access to the global rights of Foresight’s FST-100, a topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone. FST-100 is a

EDO-S101 combines the DNA damaging effect of bendamustine with the pan-histone deacetylase inhibitor (HDACi) vorinostat, with the aim of increasing the efficacy of the alkylator through the HDACi-mediated

PI causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function

Under the company’s contract with HHS-BARDA, the trial has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness

The approval is based on the benefit observed with the Perjeta regimen in achieving pathological complete response (pCR) in the neoadjuvant treatment of HER2-positive early breast cancer (eBC).

The trial evaluated the efficacy and safety of two different plecanatide treatment doses (3mg and 6mg), taken as a tablet once-a-day, in 1337 adults with CIC. According to

The one-year open-label, multi-center, single arm ADRESU trial is designed to evaluate the efficacy and safety of periurethral injection of autologous adipose derived regenerative cells for the treatment